| |
sTREM2, pg/mL
|
p trend
|
|---|
|
< 247.45
|
247.45–401.27
|
401.27–651.60
|
≥ 651.60
|
|---|
|
Median (pg/mL)
|
172.16
|
323.62
|
503.15
|
901.40
| |
|
The primary outcome: death or cardiovascular events
|
|
No. of cases (%)
|
56 (6.8)
|
63 (7.7)
|
66 (8.0)
|
103 (12.6)
|
< 0.001
|
|
Unadjusted HR
|
1.00
|
1.13 (0.79–1.61)
|
1.19 (0.83–1.70)
|
1.93 (1.40–2.68)
|
< 0.001
|
|
Multiple-adjusted HR*
|
1.00
|
1.01 (0.70–1.46)
|
1.01 (0.70–1.45)
|
1.57 (1.11–2.21)
|
0.002
|
|
Death
|
|
No. of cases (%)
|
32 (3.9)
|
31 (3.8)
|
45 (5.5)
|
78 (9.5)
|
< 0.001
|
|
Unadjusted HR
|
1.00
|
0.97 (0.59–1.59)
|
1.43 (0.91–2.24)
|
2.56 (1.69–3.86)
|
< 0.001
|
|
Multiple-adjusted HR *
|
1.00
|
0.76 (0.46–1.25)
|
1.06 (0.67–1.69)
|
1.68 (1.09–2.60)
|
< 0.001
|
|
Cardiovascular events
|
|
No. of cases (%)
|
39 (4.7)
|
47 (5.7)
|
40 (4.9)
|
54 (6.6)
|
0.19
|
|
Unadjusted HR
|
1.00
|
1.21 (0.79–1.85)
|
1.04 (0.67–1.61)
|
1.46 (0.97–2.21)
|
0.09
|
|
Multiple-adjusted HR *
|
1.00
|
1.14 (0.74–1.75)
|
0.97 (0.62–1.52)
|
1.36 (0.88–2.10)
|
0.17
|
|
Death or severe disability
| | | | | |
|
No. of cases (%)
|
76 (9.4)
|
97 (12.1)
|
103 (13.0)
|
145 (18.6)
|
< 0.001
|
|
Unadjusted OR
|
1.00
|
1.32 (0.96–1.81)
|
1.43 (1.05–1.96)
|
2.19 (1.63–2.95)
|
< 0.001
|
|
Multiple-adjusted OR *
|
1.00
|
1.14 (0.80–1.64)
|
1.09 (0.76–1.56)
|
1.53 (1.08–2.18)
|
0.01
|
|
Severe disability
| | | | | |
|
No. of cases (%)
|
44 (5.7)
|
66 (8.5)
|
58 (7.8)
|
67 (9.5)
|
0.01
|
|
Unadjusted OR
|
1.00
|
1.55 (1.04–2.30)
|
1.40 (0.93–2.09)
|
1.75 (1.18–2.59)
|
0.02
|
|
Multiple-adjusted OR*
|
1.00
|
1.39 (0.90–2.15)
|
1.10 (0.71–1.72)
|
1.40 (0.90–2.19)
|
0.29
|
- sTREM2 soluble triggering receptor expressed on myeloid cells 2, HR hazard ratio, OR odds ratio
- * Adjusted for age, sex, current smoking, alcohol drinking, time from onset to randomization, admission NIHSS score, systolic blood pressure, high-sensitivity C-reactive protein, history of hypertension, hyperlipidemia, coronary heart disease, and diabetes mellitus, use of antihypertensive and lipid-lowering medications, family history of stroke, stroke subtype and randomized treatment
